Seres Therapeutics Inc. (MCRB) Stock Price Down 2.7%
Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price fell 2.7% during trading on Wednesday . The stock traded as low as $13.63 and last traded at $13.84, with a volume of 1,160,201 shares changing hands. The stock had previously closed at $14.22.
Several research firms have commented on MCRB. FBR & Co cut their price target on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a report on Friday, August 12th. Leerink Swann reiterated a “buy” rating and issued a $12.00 price objective on shares of Seres Therapeutics in a research note on Thursday, August 11th. Canaccord Genuity reiterated a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research note on Monday, August 1st. Bank of America Corp. lowered Seres Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 1st. Finally, Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.57.
The firm’s market cap is $578.33 million. The company has a 50 day moving average price of $10.86 and a 200-day moving average price of $24.28.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/seres-therapeutics-inc-mcrb-stock-price-down-2-7.html
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.24. The business had revenue of $3 million for the quarter, compared to analyst estimates of $4.20 million. During the same period in the prior year, the company posted ($1.45) EPS. Seres Therapeutics’s quarterly revenue was up NaN% on a year-over-year basis. Equities research analysts anticipate that Seres Therapeutics Inc. will post ($2.32) earnings per share for the current year.
In other Seres Therapeutics news, insider John G. Aunins sold 9,390 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $10.87, for a total transaction of $102,069.30. Following the completion of the transaction, the insider now directly owns 192,125 shares in the company, valued at $2,088,398.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Roger Pomerantz sold 56,789 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $29.81, for a total transaction of $1,692,880.09. Following the transaction, the chief executive officer now owns 240,481 shares of the company’s stock, valued at $7,168,738.61. The disclosure for this sale can be found here. Company insiders own 41.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Birchview Capital LP bought a new stake in Seres Therapeutics during the second quarter worth $145,000. Pacad Investment Ltd. bought a new stake in Seres Therapeutics during the second quarter worth $198,000. First Mercantile Trust Co. bought a new stake in Seres Therapeutics during the second quarter worth $229,000. GSA Capital Partners LLP bought a new stake in Seres Therapeutics during the second quarter worth $273,000. Finally, American International Group Inc. boosted its stake in Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock worth $298,000 after buying an additional 5,290 shares during the last quarter. Institutional investors and hedge funds own 78.28% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.